Exhibit 99.1


Cytogen Restructures AxCell Biosciences Subsidiary to Support Company Focus on
Oncology Product Marketing and Development


PRINCETON, N.J., Sept. 16 /PRNewswire-FirstCall/ -- Cytogen Corporation (Nasdaq:
CYTO - News), a biopharmaceutical company with an established and growing
product line in oncology, today announced a realignment of its AxCell
Biosciences subsidiary in an effort to reduce expenses and position Cytogen for
stronger long-term growth in oncology. The plan, which includes a 75% reduction
in workforce at AxCell Biosciences, will allow continued research related to the
role of novel proteins and signal transduction pathways in disease progression
through both external collaborations and internal data mining.

"This restructuring is a reflection of both the evolving opportunities in
functional proteomics research as well as the realities of current market
conditions," said Michael D. Becker, interim chief executive officer of AxCell
Biosciences. "While AxCell will continue to pursue promising opportunities in
the area of signal transduction research, this move reinforces Cytogen's stated
corporate objective of developing and marketing oncology products."

In accordance with the new plan, AxCell has reduced its staff by approximately
75%, suspended certain projects, and implemented several other cost-saving
measures. This action is expected to lower Cytogen's annual operating expenses
by approximately $1.4 million beginning in the fourth quarter of 2002.

"Cytogen's long-term strategy and business plan remain on track," said H. Joseph
Reiser, Ph.D., president and chief executive officer of Cytogen Corporation.
"Adjusting AxCell's cost structure will position us to meet our financial
objectives and continue to build on the strengths of our core oncology business
strategy."

Following the restructuring, AxCell will continue to support key research
projects that are in the later stages of development as well as those programs
that involve the most productive research collaborations. The Company is moving
aggressively forward in evaluating and prioritizing the programs that offer the
greatest commercial potential and will continue to explore strategic
alternatives for AxCell through its investment banker.

"As the potential market applications for proteomics research continue to
evolve, AxCell offers a very balanced and adaptable business model," concluded
Becker. "This restructuring allows us to reduce costs while maintaining many of
the organization's core competencies."



About Cytogen Corporation

Cytogen Corporation of Princeton, NJ is a biopharmaceutical company with an
established and growing product line in prostate cancer and other areas of
oncology. Currently marketed products include ProstaScint(R) (a monoclonal
antibody-based imaging agent used to image the extent and spread of prostate
cancer); BrachySeed(TM) I-125 and Pd-103 (two uniquely designed, next-
generation radioactive seed implants for the treatment of localized prostate
cancer); and Quadramet(R) (a skeletal targeting therapeutic radiopharmaceutical
marketed for the relief of bone pain in prostate and other types of cancer).
Cytogen is evolving a pipeline of oncology product candidates by developing its
prostate specific membrane antigen, or PSMA, technologies, which are exclusively
licensed from Memorial Sloan-Kettering Cancer Center. AxCell Biosciences of
Newtown, PA, a subsidiary of Cytogen Corporation, is engaged in the research and
development of novel biopharmaceutical products using its portfolio of
functional proteomics solutions and collection of proprietary signal
transduction pathway information. For more information, visit www.cytogen.com
and www.axcellbio.com.

This press release contains certain "forward-looking" statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Information in
this press release, which is not historical, is forward-looking and involves a
number of risks and uncertainties. Investors are cautioned not to put any undue
reliance on any forward-looking statement. The Company's actual results may
differ materially from the Company's historical results of operations and those
discussed in the forward-looking statements for various reasons, including, but
not limited to the Company's ability to carry out its business plan, to
successfully develop and commercialize acceptance of its products such as
ProChart(TM), to determine and implement the appropriate strategic initiative
for its AxCell Biosciences subsidiary, ability to fund development necessary for
existing products and for the pursuit of new product opportunities, the risk of
whether products result from development activities, protection of its
intellectual property portfolio, ability to integrate in-licensed products such
as BrachySeed(TM), ability to establish and successfully complete clinical
trials where required for product approval, the risk associated with obtaining
the necessary regulatory approvals, shifts in the regulatory environment
affecting sale of the Company's products such as third-party payor reimbursement
issues, dependence on its partners for development of certain projects, the
ability to obtain foreign regulatory approvals for products and to establish
marketing arrangements in countries where approval is obtained, continued
listing of the Company's common stock on the Nasdaq National Market, and other
factors discussed in Form 10-K for the year ended December 31, 2001 and from
time-to-time in the Company's other filings with the Securities and Exchange
Commission. The Company specifically disclaims any intention or duty to update
any forward-looking statements, and these statements represent the Company's
current outlook only as of the date given.